A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
Public ClinicalTrials.gov record NCT00384852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy in Closed Fractures of the Humerus
Study identification
- NCT ID
- NCT00384852
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
- rhBMP-2/CPM Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- Jan 31, 2010
- Completion
- Jan 31, 2010
- Last update posted
- Feb 27, 2013
2007 – 2010
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Aurora | Colorado | 80012 | — |
| Not listed | Denver | Colorado | 80204 | — |
| Not listed | Clearwater | Florida | 33756 | — |
| Not listed | St. Petersburg | Florida | 33781 | — |
| Not listed | Brooklyn | New York | 11220 | — |
| Not listed | Monroe | North Carolina | 28112 | — |
| Not listed | Toledo | Ohio | 43606 | — |
| Not listed | State College | Pennsylvania | 16801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00384852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2013 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00384852 live on ClinicalTrials.gov.